Endometriosis Opportunity CiceroDx focuses on endometriosis diagnostics with ReceptivaDx covering all stages, presenting a targeted selling point to hospitals and fertility clinics seeking validated tests for a large patient population.

NIH Backing NIH Phase II SBIR Fast Track grant indicates credibility and potential for expanded research collaborations and funding-backed pilots with academic medical centers.

Early Stage Size Small company scale (2-10 employees) suggests flexibility and potential for rapid decision cycles with key stakeholders, but also highlights the need for channel partnerships and CRO collaborations to scale.

Revenue Growth Potential Current revenue range and prior funding show traction; potential upsell opportunities with IVF centers, fertility networks, and women’s health programs seeking expanded diagnostic offerings.

Education & Awareness Past education campaigns and industry partnerships position CiceroDx to leverage co-marketing with fertility clinics and patient advocacy groups to drive test adoption and awareness in understudied patient populations.